<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We followed up 153 patients with biopsy-proven primary systemic <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> to determine their risk for <z:hpo ids='HP_0011009'>acute</z:hpo> nonlymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> or a <z:e sem="disease" ids="C0026986" disease_type="Neoplastic Process" abbrv="MDS">dysmyelopoietic syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In 10 patients cytogenetic abnormalities developed consistent with alkylator-induced damage to hematopoietic cells </plain></SENT>
<SENT sid="2" pm="."><plain>In this group, the total melphalan dose ranged from 476 to 2450 mg (median, 1764 mg) administered over 21 to 92 months (median, 38 months) </plain></SENT>
<SENT sid="3" pm="."><plain>Eight of the 10 patients died as a direct result of <z:hpo ids='HP_0001876'>pancytopenia</z:hpo>, 1 died of progressive renal amyloid, and 1 remains alive with persistent complex cytogenetic abnormalities </plain></SENT>
<SENT sid="4" pm="."><plain>Four patients had <z:hpo ids='HP_0011009'>acute</z:hpo> nonlymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>; 5 had a <z:e sem="disease" ids="C0026986" disease_type="Neoplastic Process" abbrv="MDS">dysmyelopoietic syndrome</z:e>; and 1 had a nondiagnostic bone marrow examination </plain></SENT>
<SENT sid="5" pm="."><plain>Although only 6.5% of the entire group had <z:hpo ids='HP_0001909'>leukemia</z:hpo> or a <z:e sem="disease" ids="C0026986" disease_type="Neoplastic Process" abbrv="MDS">dysmyelopoietic syndrome</z:e>, the actuarial risk in patients surviving 3.5 years was 21% </plain></SENT>
<SENT sid="6" pm="."><plain>Median survival from <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0026986" disease_type="Neoplastic Process" abbrv="MDS">dysmyelopoietic syndrome</z:e> or <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> was 8.1 months </plain></SENT>
</text></document>